Key Takeaways
- • Twenty-three biotechnology companies launched initial public offerings in the first three quarters of 2026, nearly triple the eight biotech IPOs recorded in all of 2025.
- • Biotech listings are running against a broader IPO slowdown, as technology deals stall, according to the Wall Street Journal.
- • Rising biopharma mergers and acquisitions are lifting overall biotech exit activity, supporting the IPO recovery.
- • Generalist investors continue to favor technology over biotech, and the cost of capital for biotech companies remains high, which leaves the recovery fragile.
- • TRex Bio and Retension are among the companies cited in coverage of the current listing window.
Summary
Biotechnology companies are moving to public markets while the wider IPO market slows. Twenty-three biotechs launched initial public offerings in the first three quarters of 2026, according to the Wall Street Journal, compared with eight for all of 2025. The Journal's headline frames the period as one in which biotech listings are advancing while technology deals stall.
The rebound follows two years of a quiet IPO window for the sector. Commentators have linked the recovery in part to a surge in biopharma mergers and acquisitions, which has pushed overall biotech exits upward. The pickup is well below the 2021 peak, when more than 100 biotechs priced initial offerings and together raised nearly $15 billion, a figure cited as historical context.
Several constraints remain. Industry commentary notes that generalist investors continue to avoid biotech in favor of technology, and that the cost of capital for biotech companies is still elevated. One assessment argues the recent activity is not a one-off, while others describe the recovery as fragile. TRex Bio and Retension are among the companies referenced in coverage of the current window.
The rebound follows two years of a quiet IPO window for the sector. Commentators have linked the recovery in part to a surge in biopharma mergers and acquisitions, which has pushed overall biotech exits upward. The pickup is well below the 2021 peak, when more than 100 biotechs priced initial offerings and together raised nearly $15 billion, a figure cited as historical context.
Several constraints remain. Industry commentary notes that generalist investors continue to avoid biotech in favor of technology, and that the cost of capital for biotech companies is still elevated. One assessment argues the recent activity is not a one-off, while others describe the recovery as fragile. TRex Bio and Retension are among the companies referenced in coverage of the current window.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.